Replies to post #29899 on Biotech Values

[ThomasS]

GTCB: I have to admit astonishment at the current PPS. By any reasonable thesis, GTCB should've reached $2.50 or more after the CHMP reversal.
The only rational possibility is due to the fact that the stock was trading at $.90 just prior.

[corky]

for the bio tech investor
watch cnbc at 8:30

the fda will be on

[DewDiligence]

GTCB Possible/Probable 2006 News
Flow (addendum from GTCB ymb):

>>
by: DewDiligence
06/09/06 08:20 am
Msg: 33441 of 33444

>Dew, don't you expect GTCB to establish a partnership for Atryn-HD for the US market in 2006?<

Actually, I do not see this happening in 2006. GTC has already done the heavy lifting of getting FDA approval for the unusual phase-3 trial design and opening up trial centers around the world. I’m not sure a big-name partner could offer GTC anything of great consequence until we are closer to the prospective U.S. ATryn launch in 2008. Moreover, GTC is no longer in a precarious financial condition, so they don’t need to strike a deal just to bring in some milestone cash. Regards, Dew

[Posted as a reply to: Msg 33436 by mblimon2000]
<<